Michael Skipworth

Michael Skipworth

Auto-generated profile, based on publicly available information

Michael Skipworth

Department of Neurosciences, University of California, San Diego

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2023 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
EBEce Bayram
Ece Bayram
HLHongliang Liu
Hongliang Liu
SLSheng Luo
Sheng Luo
DLDaniel G. Di Luca
Daniel G. Di Luca
MSMichael Skipworth
Michael Skipworth
ILIrene Litvan
Irene Litvan

27 July 2026 in Clinical Neurophysiology
Verified
Journal Article
Open access
KLKatherine Longardner
Katherine Longardner
PRPratusha Reddy
Pratusha Reddy
DSDanielle Shoshany
Danielle Shoshany
MSMichael Skipworth
Michael Skipworth
DSDawn M. Schiehser
Dawn M. Schiehser
Kurtulus IzzetogluKurtulus Izzetoglu
Kurtulus Izzetoglu

27 July 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
TSTamoghna Saha
Tamoghna Saha
MKMuhammad Inam Khan
Muhammad Inam Khan
KLKatherine Longardner
Katherine Longardner
BSBarak Sabbagh
Barak Sabbagh
KZKaiwen Zheng
Kaiwen Zheng
Joseph WangJoseph Wang
Joseph Wang
Precision management of Parkinson’s disease (PD) requires frequent levodopa (L-dopa) dose adjustments, yet current monitoring relies on subjective symptom reporting and infrequent blood testing. Here, we present a soft, fingertip-mounted wearable platform for continuous, noninvasive L-dopa monitoring. By combining osmotically harvested passive sweat with soft hydrogels, a potentiometric sensing strategy, and individualized calibration, the platform estimates blood L-dopa information from sweat without external power or iontophoresis. Strong correlations between sweat and high-performance liquid chromatography (HPLC)-measured blood L-dopa concentrations were observed in healthy ( P r = 0.85 ) and PD subjects ( P r = 0.88 ) following a single immediate-release L-dopa/carbidopa dose. Low motor symptom scores aligned with peak L-dopa levels, confirming pharmacodynamic relevance. L-dopa cleared faster in PD patients despite similar bioavailability to healthy subjects, while recorded hemodynamic responses showed short hypotensive trends for both groups. Machine learning identified sweat and blood pressure as key contributors toward accurate estimation of blood L-dopa levels (mean absolute error = 2.02 µM vs. ground truth). Overall, our easy-to-use, energy-efficient wearable supports real-time, stimulation-free monitoring, potentially enabling at-home dosage adjustments and paving the way for future autonomous closed-loop L-dopa therapeutic system development.